Quick Facts

• May be utilized as a treatment option for specific infections of the urinary tract.
• Provides management for certain gastrointestinal infections caused by susceptible organisms.

Floxatral (norfloxacin) is an established therapeutic agent approved for managing bacterial infections in various systems of the body. The primary uses for this medication include addressing infections of the urinary tract, such as cystitis, pyelitis, and pyelonephritis, when caused by susceptible bacteria. It is also indicated for use in the treatment of certain infectious conditions within the gastrointestinal tract.

This medication is part of a class of antibacterial drugs that function to stop or kill the growth of bacteria causing illness. It is not intended for use against viral infections, such as the common cold or flu. Like all prescription agents, the determination to use this medication must be made by a healthcare provider after a complete assessment of the infection type and patient medical history.

Floxatral (ofloxacin) is a fluoroquinolone antibiotic used to treat specific bacterial infections in adults and certain pediatric patients. It's generally prescribed for infections where the risk of serious side effects is considered lower than the potential benefit, or when alternative treatments are unavailable.

Eligible Use

Floxatral is indicated for treating various infections, including but not limited to:

• Complicated Urinary Tract Infections (UTIs).
• Lower respiratory tract infections, such as certain types of pneumonia.
• Skin and soft-tissue infections.
• Prostatitis (chronic bacterial).
• Certain sexually transmitted diseases, like uncomplicated urethral and cervical gonorrhea.

Contraindications (Cannot Use)

Do not use Floxatral if you have a known history of hypersensitivity to ofloxacin or other fluoroquinolones. Additionally, it is generally contraindicated for patients with:

• A history of tendinitis or tendon rupture associated with any fluoroquinolone.
• A diagnosis of myasthenia gravis due to the potential for exacerbation of muscle weakness.
• Concomitant use with the muscle relaxant tizanidine.

Interactions with other medicines and products

Floxatral (Ofloxacin) has officially documented interactions with several classes of medicinal products and other substances, as detailed in governmental regulatory labeling.

Affecting Floxatral Levels (Absorption/Clearance)

Co-administration with preparations containing divalent or trivalent cations (such as mineral antacids containing magnesium or aluminum, iron salts, sucralfate, or zinc preparations) reduces the absorption of Floxatral. To mitigate this effect, official regulatory documents require Floxatral to be administered 2 hours before or 2 hours after these cation-containing products. Drugs that affect renal tubular secretion, including Probenecid, Cimetidine, Furosemide, and Methotrexate, may decrease the total clearance of Floxatral, potentially increasing its systemic concentration.

Affecting Risk and Specific Effects

Concomitant use with drugs that lower the cerebral seizure threshold, such as Theophylline or certain Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) like Fenbufen, can increase the risk of central nervous system excitation or seizures. Floxatral should be used with caution alongside other medications known to prolong the QT interval (e.g., Class IA and III antiarrhythmics, tricyclic antidepressants) due to the potential for additive effects. When used with Vitamin K antagonists (e.g., Warfarin), there is an officially documented potential for increased coagulation parameters; therefore, coagulation tests require monitoring. Diabetic patients co-administered oral hypoglycemic agents (e.g., Glibenclamide) should be closely monitored for hypoglycemia. Concomitant use with corticosteroids is associated with an increased risk of tendinitis and tendon rupture.

Mechanism of Action: Targeted Bactericidal Activity

Floxatral (Norfloxacin) exerts its action by targeting and inhibiting two essential bacterial Type II Topoisomerases: DNA Gyrase and Topoisomerase IV. The drug acts as an enzyme inhibitor by binding to the DNA-Topoisomerase complex after the bacterial DNA has been cleaved. This binding stabilizes the intermediate complex, preventing the essential re-ligation process. These enzymes are required for all bacterial genetic processes, including replication, transcription, and repair.

Cascade and Physiological Consequence

The inhibition of the topoisomerases initiates a lethal intracellular cascade. The consequent accumulation of DNA double-strand breaks inside the bacterial cell overwhelms the cell's repair capacity and triggers a self-activated death response. This bactericidal mechanism leads to the irreversible loss of bacterial cell viability. This mechanism is constrained by bacterial defense, including target-modifying mutations that reduce drug affinity and the overexpression of efflux pumps that reduce effective intracellular concentration.

How to Use Floxatral: Official Administration Guidelines

The usage of Floxatral (norfloxacin) is dictated by specific, label-based instructions that govern the route, frequency, and conditions of intake. The medicine is available in two forms: a tablet for systemic treatment and an ophthalmic solution for localized treatment of eye infections.

Oral Dosing and Frequency

Administration Requirements

The oral tablet must be swallowed whole with a full glass of water. It is a requirement that the medication be taken on an empty stomach to ensure proper systemic absorption. This means the dose must be separated from any meal, milk, or other dairy product by at least 1 hour before or 2 hours after consumption.

Special Procedural Conditions

Administration must be scheduled at least 2 hours away from products containing iron, zinc, aluminum, or magnesium (such as antacids or mineral supplements) to prevent binding of the medication. Sufficient fluid intake should be maintained throughout the treatment period.

Population-Specific Use

For patients diagnosed with significant renal impairment (creatinine clearance le 30 mL/min/1.73 m^2), the standard twice-daily oral frequency is reduced to 400 mg once daily. The safety and efficacy of the oral tablet form have not been established for pediatric patients, but the ophthalmic solution is approved for use in children over one year of age.

Research Evidence / Overview of Studies for Floxatral

Evidence for Use in Urinary Tract Infections (UTI)

Research has explored the use of Norfloxacin in conditions associated with acute or disruptive episodes, including uncomplicated urinary tract infections (UTIs). Studies focusing on this short-term use often include Randomized Controlled Trials (RCTs) where the medicine was compared against other treatments. Investigators monitored outcomes related to systemic or functional imbalance, specifically examining bacteriological cure rates and clinical response, which reflected how symptoms evolved in the observed populations. Comparative trials in adult women reported patterns related to symptom resolution and patterns of recurrence when Norfloxacin was studied in the context of prevention.

Evidence for Prophylaxis in High-Risk Liver Conditions

Norfloxacin was also evaluated in long-term research for its role in preventing certain infections, such as Spontaneous Bacterial Peritonitis (SBP), in high-risk adult patients with advanced liver cirrhosis. The evidence base here consists of Long-term RCTs that often compare Norfloxacin to a placebo, along with systematic reviews. These studies monitored outcomes reflecting daily functioning, primarily the incidence of SBP and overall patient survival over extended periods. Analyses of these studies have described patterns observed in the incidence of SBP compared to patients receiving a placebo. Findings related to overall patient survival were observed in some studies, but data from different trials have been mixed or less consistent.

What is Still Uncertain About the Research Base

Research highlights areas where certainty remains low. Specifically, research findings for the oral formulation for complicated kidney infections (pyelonephritis) did not sufficiently characterize outcomes, which is reflected in its established uses in certain regions. Furthermore, the concern that long-term continuous use may favor the development of resistant bacteria was observed in some studies, which highlights a primary area where more investigation is needed to expand the evidence landscape. The results apply only to the populations studied, and data for certain specific patient groups remain insufficient.

Key Studies & References

1. Antibiotic prophylaxis to prevent spontaneous bacterial peritonitis in people with liver cirrhosis: a network meta-analysis (2020)

Common questions about Floxatral (FAQ)

Q: What is Floxatral used for?

A: Floxatral is a prescription medication approved for specific medical indications. It is classified as an alpha-1 blocker. Its approved uses are primarily related to managing symptoms associated with benign prostatic hyperplasia (BPH) and certain other conditions as determined by a healthcare provider.

Q: How does Floxatral work?

A: Floxatral is understood to function by blocking specific receptors in the body. This action may result in the relaxation of muscles in the prostate and bladder neck. These effects are thought to contribute to improvement in urine flow and reduced BPH symptoms. Further details on its mechanism are available in its prescribing information.

Q: Is Floxatral effective for BPH?

A: Clinical studies investigating Floxatral in men with BPH have observed effects on urinary flow and reported symptom scores. Evidence suggests that the medication is associated with a beneficial impact on these parameters compared to placebo in controlled trials. Individual responses to treatment may vary.

Q: What are the common side effects of Floxatral?

A: The most frequently reported adverse effects in clinical trials include dizziness, headache, and tiredness. Other reported effects may include nasal congestion or certain circulatory effects. It is important to discuss all potential side effects with a healthcare professional. A comprehensive list of reported events is contained in the medication's label.

How to Store and Dispose of Floxatral (Norfloxacin)

The official storage conditions for Floxatral are mandated to maintain the stability of the medicine.

Storage Requirements

Floxatral must be stored at Controlled Room Temperature, specifically between 20 C to 25 C (68 F to 77 F). The medicine must be kept in its original container, which must remain tightly closed to protect it from moisture. Regulatory documents explicitly state that the solution form of the product must not be frozen.

All forms of Floxatral must be stored out of the sight and reach of children to prevent accidental exposure.

Disposal Instructions

Expired or unused Floxatral must be handled as pharmaceutical waste. It is forbidden to dispose of the medicine via wastewater (e.g., flushing down a toilet or pouring down a sink) or household trash. Disposal must be performed according to local requirements and designated drug take-back programs.